Shares In Cochlear (ASX:COH) Plunge Over 35% As FY26 Guidance Is Slashed By Nearly A Third! Is It A Buy The Dip Opportunity?

If you own shares in Cochlear (ASX:COH), you had a pretty bad morning. The company delivered one of the most significant earnings guidance downgrades in its listed history this morning, cutting its FY26 underlying net profit guidance to A$290–330m from a previously disclosed range of A$435–460m. The revision (a reduction of roughly 30% at the midpoint) sent Cochlear’s share price down approximately 35% in early trade, erasing well over A$4bn in market capitalisation in a single session. To understand why the market has responded so severely, it is worth examining not just the numbers but the nature of the deterioration underlying them.

The News Out Of Cochlear That Investors Hated

The announcement, released this morning prior to market open, cited a convergence of five distinct headwinds, each individually manageable but collectively material. They are worth itemising precisely.

First, and most significant, developed market cochlear implant volumes have been softer than expected since January. Revenue for the quarter was flat in constant currency, representing a sharp deterioration from the growth trajectory signalled at the HY26 result in February. In the US, volumes were in line with expectations until mid-February before declining through March.

Referrals from the hearing aid channel (a key source of patient pipeline for cochlear implants in the adult and seniors segment) have fallen, consistent with a broader pullback in discretionary activity in that channel. In Western Europe, hospital capacity constraints and industrial action in Italy and Spain have restricted surgical throughput, producing growing waiting lists in the UK and Germany. Second half sales growth across cochlear implants is now expected at 2–6% in constant currency, down from a rate that had been running materially above this level. Long story short: Turns out Cochlear’s products really are discretionary.

Second, the conflict in the Middle East has introduced direct commercial disruption. Cochlear expects order cancellations and delivery delays to some countries in the region, with potential provisions for receivables of up to A$10m net profit impact flagged explicitly. Third, the reduction in production volumes flowing from lower demand is expected to compress gross margin by approximately one percentage point (a roughly A$20m net profit impact) due to lower overhead recoveries as fixed manufacturing costs are spread across a smaller unit base. This is a classic volume deleverage effect.

Fourth, the company is accelerating its cost base reshaping programme, which was signalled at the HY26 result but has been brought forward in response to current conditions. The restructuring charge is expected to run to A$18–25m above the line in FY26.

Fifth, the Australian dollar has strengthened materially since the prior guidance was set — from 66 cents to 71 cents against the US dollar and from 56 to 61 cents against the euro, generating a roughly A$25m after-tax earnings headwind. Cochlear derives the overwhelming majority of its revenue offshore, making it acutely sensitive to a rising Australian dollar.

Shares in Cochlear Were Slammed By >30%! Why?

A 30% reduction in earnings guidance would, in most circumstances, be expected to produce a share price decline of broadly similar magnitude. The 35% fall observed this morning implies the market is pricing in something additional: multiple compression.

Cochlear has historically traded at a significant premium to the broader ASX (typically in the range of 40–50x earnings) justified by its near-monopoly position in cochlear implants, the predictability of its installed-base-driven Services revenue, and a long runway of clinical and demographic growth.

That premium was underwritten by two assumptions: that developed market surgical volumes were structurally growing, and that the adult and seniors segment was a reliable double-digit growth driver. The reality is that this morning’s announcement challenges both assumptions directly. The disclosure that consumer sentiment in the US has reached historic lows and is now affecting discretionary healthcare decisions (including hearing interventions) raises the question of whether some component of the softness is cyclical, or something more durable.

Management’s language around the need to “medicalise” hearing loss suggests the company itself acknowledges that clinical perception of cochlear implants, particularly in the adult segment, remains an ongoing commercial challenge rather than a solved problem. That is a different kind of risk to model than a temporary surgical backlog. The gross margin impact from volume deleverage is also a structural warning sign. Cochlear’s cost base is heavily fixed; when units slow, margins compress quickly.

Looking Forward: Is It a Buy Now?

Management reaffirmed confidence in its innovation pipeline, noting two clinical studies for a drug-eluting electrode and two studies for a totally implantable cochlear implant are progressing toward regulatory approval. Services revenue continues to grow strongly, up 13% in constant currency in the third quarter, providing a floor under near-term earnings.

Investors will inevitably ask if the market has overreacted. The honest answer, in Cochlear’s case, is: possibly, but with important caveats. Prior to this morning’s announcement, consensus FY27 EPS estimates sat at approximately A$7.54 (representing an A$543m profit), implying a pre-fall P/E of around 38x on a stock trading near A$168. At the post-fall price of approximately A$109, and before any analyst revisions, that FY27 estimate implies a P/E of roughly 14.5x — a multiple Cochlear has not traded at in over a decade, and well below its long-run average of 38–50x.

The problem is that the A$7.54 FY27 estimate will not survive today’s update intact. Analysts will need to account for a lower earnings base entering FY27, a structurally softer US referral channel, reduced China pricing and an Australian dollar that shows no near-term signs of weakening. A 20–25% downward revision to FY27 consensus is plausible, which would place earnings closer to A$5.75–6.00 per share (or a $414-432m profit) which implies a P/E of 18–19x at current prices. That is still undemanding relative to COH’s history and the quality of the underlying franchise.

Our view

The long-term investment case and tailwinds are in tact: Namely an ageing global population, growing clinical evidence linking untreated hearing loss to dementia, and a genuinely defensible market position. The near-term earnings trajectory does not. For patient investors with a three-to-five year horizon, today’s price likely represents the most attractive entry point in years. For those reliant on earnings recovery in FY27, the risk of a second guidance revision cannot be dismissed. Or even if the company meets its guidance, any FY27 guidance that is backwards relative to FY26 could sour things further.

Few companies will say anything other than that the longer-term looks bright. However, with official guidance now at A$290–330m and the operating environment now and beyond FY26 still uncertain, Cochlear enters the second half of FY26 with less earnings visibility than it has had at any comparable point in recent years. Today’s update is less a singular shock than a recalibration. The market, having carried the stock at premium multiples for a sustained period, is recalibrating accordingly.